NCT07406204Phase 4Not yet recruiting
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
Comparative Clinical Efficacy of Tofacitinib Versus Methotrexate in Severe Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Randomized Controlled Trial
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 4
- Sponsor
- Hayat Abad Medical Complex, Peshawar
- Participants (registry)
- 78
- Start
- February 2026 (planned)
- Primary completion
- August 2026
- Study completion
- August 2026
- Last registry update
- February 2026
- Countries
- —
Conditions studied: Alopecia Areata, Alopecia Totalis (AT), Alopecia Universalis
Interventions: Tofacitinib, Methotrexate
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.